drugset / Trial / NCT01530022

Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects

NCT01530022

Phase 1 Completed 60 enrolled UCB Pharma
RandomizedCrossoverDouble-blind

Summary

The primary objective of this Phase 1 crossover study is to evaluate the neuropsychological effects of Lacosamide (LCM) compared to Carbamazepine Immediate Release (CBZ-IR) after administration in healthy subjects. Safety, tolerability, and pharmacokinetic data will also be collected.

Timeline

Start
2012-05
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbamazepine Small molecule 200 mg Oral
Subject Lacosamide Other / unclassified 150 mg Oral

Indications

No indication recorded.